MetaVia
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
545 Concord Ave Ste 210, Cambridge, Mass...Phone Number
(857) 702-9600Website
www.metaviatx.comRevenue
-Stock Symbol
MTVAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About MetaVia
MetaVia formerly known as NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).Explore more
MetaVia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MetaVia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when MetaVia launches new products
Earning: See what the market has to say on MetaVia recently announced quarterly report
MetaVia, which may be a good buyer, showed buying intent in Masked Content Topic
Check if MetaVia has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MetaVia had a recent Job posting/layoffs
Funding: Get notified immidiatlly once MetaVia has new funding data
Congratulate Masked Content for being promoted to Masked Content at MetaVia
Check out if MetaVia is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at MetaVia
Find 2 more new buyers
Company Profile Activity
Activity Insights
MetaVia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MetaVia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MetaVia.
Most Recent Scoops
Project
MetaVia has observed a reduction of nearly 10 cm in waist circumference over eight weeks in the DA1726 48 mg cohort, believed to reflect visceral fat reduction, with full-body MRI being conducted in the current phase to confirm the source of this reduction. For context, Boehringer Ingelheim's surbuditide phase three data over more than 18 months showed 34% visceral fat reduction, and no comparable visceral fat reduction data has been reported for semaglutide or other GLP-1 agents.
Project
MetaVia has conducted non-clinical combination studies of vanoclopramide with resmetirom, achieving approximately 22% weight loss in mice without a change in food intake versus monotherapy arms, suggesting a mechanism distinct from GLP-1-driven appetite suppression that may be relevant for GLP-1 non-responders or intolerant patients. A separate combination with metformin showed improved glycemic control and modest additional weight loss versus metformin alone.
Medical Research
Project
MetaVia has planned an FDA meeting in the second half of this year to discuss the development strategy for a vanoclopramide and resmetirom combination program, including whether biopsy requirements can be avoided and whether a direct phase three entry is feasible, leveraging resmetirom's existing biopsy dataset as an approved drug.
Medical Research, Pharmaceuticals, Clinical Operations
Project
MetaVia has reported that the ongoing phase one, part three study of DA1726 in the 48 mg non-titrated cohort over eight weeks demonstrated 9.1% weight loss, improved glycemic control, and reduced liver stiffness as measured by VCTE, with moderate side effects including increased vomiting beginning to emerge at this dose level.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
MetaVia News & Media
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH Model Vanoglipel Combined with Metformin...MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial...MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels...MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MetaVia
Sign Up For FreeTo access detailed company insights
MetaVia formerly known as NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).... Read More
